Clinical Trial Update: Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) [Phase 2]

View source ↗

Summary

MGL-3196 (resmetirom), developed by Madrigal, completed a Phase 2 trial in patients with heterozygous familial hypercholesterolemia, with results posted on 2025…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• MGL-3196 (resmetirom) (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2025-12-23